PMID- 11135700
OWN - NLM
STAT- MEDLINE
DCOM- 20010426
LR  - 20181130
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 8
IP  - 6
DP  - 2000 Dec
TI  - [An experimental study on arsenic trioxide-selectively induced human 
      hepatocarcinoma cell lines apoptosis and its related genes].
PG  - 367-9
AB  - OBJECTIVE: To study the possible apoptosis-inducing effect of arsenic trioxide on 
      human hepatocarcinoma (HCC) cells, and its molecular mechanisms. METHODS: Arsenic 
      trioxide action on the cell growth, apoptosis, periodicity and the expression of 
      related genes in two human hepatocarcinoma cell lines QGY-7701 and QGY-7703, and 
      normal humanhepatic cell line L-02 in vitro was observed by MTT assay, acridine 
      orange (AO) /ethidiumbromide (EB) fluorescent staining, electron microscopy 
      detection, DNA gel electrophoresis, flow cytometry, TUNEL assay and 
      immunohistochemical staining. RESULTS: Arsenic trioxide could strongly inhibit 
      the growth of human hepatocarcinoma cells QGY-7701 and QGY-7703 with the cell 
      cycle arrested on S phase, and induce the apoptosis of the cells with bcl-2 gene 
      expression down-regulated and bax and Fas gene expression up-regulated. But 
      arsenic trioxide had no obvious effect on the normal hepatic cells. CONCLUSION: 
      Arsenic trioxide has significant selective apoptosis-inducing effect on the human 
      hepatocarcinoma cells, which is regulated by several genes. The results provide 
      the credible experimental basis for clinically treating HCC with arsenic 
      trioxide.
FAU - Liu, L
AU  - Liu L
AD  - Tumor Center, the 81st hospital of PLA, Nanjing 210002, China.
FAU - Qin, S
AU  - Qin S
FAU - Chen, H
AU  - Chen H
FAU - Wang, J
AU  - Wang J
FAU - Chen, H
AU  - Chen H
FAU - Ma, J
AU  - Ma J
FAU - Liu, W
AU  - Liu W
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (BAX protein, human)
RN  - 0 (Oxides)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0 (fas Receptor)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Arsenic Trioxide
MH  - Arsenicals/*pharmacology
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Genes, bcl-2
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Oxides/*pharmacology
MH  - Proto-Oncogene Proteins/genetics
MH  - *Proto-Oncogene Proteins c-bcl-2
MH  - S Phase/drug effects
MH  - Tumor Cells, Cultured
MH  - bcl-2-Associated X Protein
MH  - fas Receptor/genetics
EDAT- 2001/01/03 11:00
MHDA- 2001/05/01 10:01
CRDT- 2001/01/03 11:00
PHST- 2001/01/03 11:00 [pubmed]
PHST- 2001/05/01 10:01 [medline]
PHST- 2001/01/03 11:00 [entrez]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2000 Dec;8(6):367-9.